Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698387 | 1.00 | CYP19A1 (0.64) | CYP19A1MAOAMAOBKDM1ADDB1 | |
| SCHEMBL2054566 | 1.00 | CYP19A1 (0.64) | CYP19A1MAOAMAOBKDM1ADDB1 | |
| SCHEMBL2056307 | 1.00 | CYP19A1 (0.64) | CYP19A1MAOAMAOBKDM1ADDB1 | |
| SCHEMBL12859669 | 0.88 | CYP19A1 (0.60) | CYP19A1MAOAMAOBKDM1A | |
| SCHEMBL11079038 | 0.84 | CYP19A1 (0.64) | CYP19A1DDB1CRBNTNKSTNKS2 | |
| SCHEMBL4556388 | 0.80 | CYP19A1 (0.72) | CYP19A1MAOAMAOBDDB1CRBN | |
| SCHEMBL14520901 | 0.80 | CYP19A1 (0.72) | CYP19A1MAOAMAOBDDB1CRBN | |
| SCHEMBL4760568 | 0.79 | CYP19A1 (0.47) | CYP19A1KDM1ADDB1CRBN | |
| SCHEMBL11914812 | 0.79 | CYP19A1 (0.47) | CYP19A1KDM1ADDB1CRBN | |
| SCHEMBL11911761 | 0.79 | CYP19A1 (0.47) | CYP19A1KDM1ADDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283474-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-7875643-B2 | (1S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-3-azabicyclo[3.1.0]hexane; or(1S,5R)-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; schizophrenia | GLAXO GROUP LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7807698-B2 | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor | GLAXO GROUP LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-06-17 | — | — | US | disclosed |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20080227837-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| US-20080167357-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR5A, DRD5 | CYP19A1 1680/4885MAOA 1459/4885MAOB 1275/4885 |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | CHRNB3, DRD2, DRD3 | CYP19A1 311/4885MAOA 259/4885MAOB 43/4885 |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | CYP19A1 3246/4885MAOA 1579/4885MAOB 967/4885 |
| US-20080167357-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful as Modulators of Dopamine D3 Receptors | HTR5A, DRD3, HTR3C | CYP19A1 1397/4885MAOA 2017/4885MAOB 1610/4885 |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | CYP19A1 3246/4885MAOA 1579/4885MAOB 967/4885 |
| US-20080227837-A1 | Novel Compounds | HTR5A, NPY5R, DRD3 | CYP19A1 1493/4885MAOA 1352/4885MAOB 1122/4885 |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HTT, GBA2, GBA1 | CYP19A1 130/4885MAOA 765/4885MAOB 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.